Media B-Roll

First-Ever Treatment Found for Progeria

Every child showed improvement in the first-ever Progeria clinical drug trial, which was funded and coordinated by The Progeria Research Foundation

 

 

 
Home » News » Press Room » Media B-Roll

Contacts:

For The Progeria Research Foundation:
Megan Lustig (PRF)
Office: (202) 955-6222
Mobile: (301) 467-7869
mlustig@spectrumscience.com

For Boston Children’s Hospital:
Keri Stedman
(617) 919-3110
keri.stedman@childrens.harvard.edu

RELEASE DATE: September 24, 2012: Results of the first-ever clinical drug trial for children with Progeria, a rare, fatal aging disease, demonstrate the efficacy of farnesyltransferase inhibitors (FTIs). The clinical trial, completed at Boston only six years after scientists identified the cause of Progeria, showed that the FTI lonafarnib had a positive effect on weight gain, hearing, bone health and, most importantly, cardiovascular health. The study results were published today in Proceedings of the National Academy of Sciences (Epub ahead of print).

“To discover that some aspects of damage to the blood vessels in Progeria can not only be slowed by the FTI lonafarnib, but even partially reversed within just 2.5 years of treatment is a tremendous breakthrough, because cardiovascular disease is the ultimate cause of death in children with Progeria,” said Leslie Gordon, M.D., Ph.D., lead author of the study, and Medical Director of PRF, and mother of a child with Progeria.

Progeria Linked to Normal Aging Process
Previous research shows that the Progeria-causing protein progerin is also produced in the general population and increases with age. Researchers plan to continue researching the effect of FTIs, which may help scientists learn more about the cardiovascular disease that affects millions, as well as the normal aging process.

PRF’s Impressive Record
“PRF provides a model for disease research organizations, and is a good example of a successful translational research organization, moving from gene discovery to clinical treatment at an unprecedented pace,” said Dr. Kieran. “From 1999, when the organization was founded, to today, PRF has identified the genetic mutation that causes the disease, funded preclinical research, completed this trial, initiated a second trial, and is currently working with our team here at Boston Children’s Hospital to plan yet another trial with drugs that, like FTIs, have shown exciting results in Progeria cells and animal models. That’s a remarkable track record of accomplishment.”

CLICK HERE for the press release (PDF)

DOWNLOAD B-ROLL FOR YOUR STORIES HERE*:

* This footage is offered free and unrestricted for broadcast use on behalf of
The Progeria Research Foundation.

Leslie B. Gordon, MD, PhD
Clinical Trial Co-Chair
Medical Director, The Progeria Research Foundation

Download Broadcast Quality File (2:22 / 720x480 / MP4 / 161 MB)


Mark Kieran MD, PhD

Clinical Trial Principal Investigator
Director, Pediatric Medical Neuro-Oncology, Children’s Hospital Boston/Dana-Farber Cancer Institute


Download Broadcast Quality File
(1:49 / 720x480 / MP4 / 133 MB)


Audrey S. Gordon, Esq.

President and Executive Director, The Progeria Research Foundation

Download Broadcast Quality File (1:46 / 720x480 / MP4 / 127 MB)


Sandy and Steve Nighbor

Parents of Clinical Trial Participant Megan

Download Broadcast Quality File (1:49 / 720x480 / MP4 / 132 MB)


Supporting B-roll footage appears in the following order:  

  1. Megan Nighbor in 2007 during one of her first trial visits to Children’s Hospital Boston
  2. Megan at home in Wisconsin in 2010, taking the FTI medication
  3. Sandy and Steve Nighbor looking at PRF’s web site
  4. Megan at home
  5. Drs. Gordon and Kieran discuss trial data
  6. Dr. Gordon with trial participants
  7. The FTI lonafarnib

Download Broadcast Quality File (4:13 / 720x480 / MP4 / 304 MB)

To download files, please right click or option-click the link and choose "Save..."

quick links

Donate Now
Now more than ever, your contribution makes a difference.